Publication | Closed Access

Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression

Breast OncologyCancer ImmunosurveillanceImmunologyTumor ImmunityTumor-derived MicroparticlesImmune Checkpoint InhibitorBreast CancerTumor TargetingTriple-negative Breast CancerImmunotherapyMedicineCell BiologyTumor MicroenvironmentTumor BiologyPd-l1-associated Immune Suppression